Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2012Nephro-Urology MonthlyOpen Access

Lessons From the KK-Ay Mouse, a Spontaneous Animal Model for the Treatment of human Type 2 Diabetic Nephropathy

View Full Paper
Ask AI
Bookmark
Share

Key result

KK-Ay mouse serves as a useful spontaneous model for evaluating type 2 diabetic nephropathy therapies.

Why the study?

KK-Ay mice are considered a suitable spontaneous animal model for human type 2 diabetic nephropathy, but their utility for evaluating pathogenesis and treatment requires clarification.

Population

KK-Ay mice as a spontaneous animal model for type 2 diabetic nephropathy

Comparison

Various therapeutic interventions including AGE inhibitors, ACE inhibitors, ARBs, vitamin D3, and EPA

Design

Review of studies using KK-Ay mice

Authors

YTYasuhiko TominoShowa University

Discussion

Loading...

Member takes

Overview

May accelerate preclinical testing of diabetic nephropathy therapies; leaves open translation to human care.

Structured PICO

P
Population
KK-Ay mice (spontaneous animal model for human type 2 diabetic nephropathy)
I
Intervention
Various therapeutic interventions including advanced glycation end product (AGE) inhibitors (aminoguanidine, pyridoxamine), ACE inhibitors, ARBs, 1,25-dihydroxyvitamin D3, and eicosapentaenoic acid (EPA)
O
Outcome
Efficacy in the treatment of diabetic nephropathy (including amelioration of lipid peroxidation, insulin resistance, and microinflammation)surrogate

The KK-Ay mouse serves as a valuable spontaneous model for studying the pathogenesis and evaluating treatments for human type 2 diabetic nephropathy.

Limitations

  • Confirmation that the treatments studied in the KK-Ay mouse are effective in human patients with type 2 diabetic nephropathy is necessary.

Cite This Study

Yasuhiko Tomino (2012) conducted a review in Type 2 Diabetic Nephropathy. Various treatments (pyridoxamine, ACE-I, ARB, EPA) was evaluated. The KK-Ay mouse serves as a useful spontaneous animal model for evaluating the pathogenesis and potential treatments for human type 2 diabetic nephropathy.

synapsesocial.com/papers/6ab1e6684cd2c9db00de3c07https://doi.org/10.5812/numonthly.1954
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta‐analysis2007 · 125 citations
  2. 2Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice: Involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation2005 · 84 citations
  3. 31,25-Dihydroxyvitamin D3 Suppresses Renin Gene Transcription by Blocking the Activity of the Cyclic AMP Response Element in the Renin Gene Promoter2007 · 493 citations
  4. 41,25-Dihydroxyvitamin D3decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat2004 · 226 citations